Merck is working with Atomwise to explore the frontiers of drug discovery using artificial intelligence and machine learning.
Working to Fight an Epidemic
Ebola Virus’ high lethality have left thousands dead and tens of thousands orphaned since 1976. From a field of thousands of approved medicines, Atomwise discovered a drug candidate with no previous antiviral application that blocked Ebola infectivity across virus strains from multiple epidemics.
Left: Ebola virus replicating in a human host cell.
Computing New Treatments for MS
Multiple Sclerosis afflicts 2.5 million people with debilitating neurological symptoms, underscoring a vital need for new medicines. Atomwise explored 8.2 million molecules to discover a protein-protein inhibitor for the treatment of multiple sclerosis that is blood-brain-barrier penetrant, orally available, and highly efficacious in animals.
Right: An untreated EAE mouse. Far right: An EAE mouse treated with an Atomwise-predicted small molecule therapy.
Powered by AtomNet™
The first deep leaning neural network for structure-based drug design and discovery.